Skip to content

Integra LifeSciences IART Financing Cash Flow

Financing Cash Flow at other companies

Stryker logo
StrykerSYK
-$1.51B-160%
Axogen logo
AxogenAXGN
$59.51M+2,398%
Globus Medical logo
Globus MedicalGMED
$18.2M+103%
AbbVie logo
AbbVieABBV
$919M+173%
Medtronic logo
MedtronicMDT
-$888M+33.9%
STERIS logo
STERISSTE
-$97.9M+45.0%

Other financials

Income statement

See full
Revenue$391.9M+2.4%
Gross profit$217.0M+11.6%
Operating income$11.5M+174%
Net income-$4.6M+81.7%
EPS (diluted)-$0.06+81.8%

Balance sheet

See full
Cash & equivalents$236.8M-1.0%
Total debt$2.0B+3.2%
Total equity$1.0B-31.6%
Total assets$3.6B-11.7%

Cash flow

See full
Operating cash flow$9.8M+187%
CapEx$14.8M-48.7%
Free cash flow-$5.0M+87.4%

Valuation

See full
Market cap$1.38B-56.8%
Enterprise value$3.12B-26.7%
P/S0.8×-1.1×

Profitability

See full
Gross margin51.9%-1.6pp
Operating margin-29.8%-30.3pp
Net margin-30.1%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-38.6%
Debt / equity1.9×+0.6×
Current ratio3.4×+2.2×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Integra LifeSciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Integra LifeSciences's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Integra LifeSciences's financing cash flow?
Integra LifeSciences (IART) reported financing cash flow of $8.3M in Q1 2026.
How has Integra LifeSciences's financing cash flow changed year-over-year?
Integra LifeSciences's financing cash flow decreased by 76.5% year-over-year, from $35.38M to $8.3M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.